5ml Mounjaro: the second dose, explained

Is 5 mg Mounjaro the same medicine as the other strengths?

Yes. Whether the pen is labelled 2.5 mg, 5 mg, 10 mg or 15 mg, the active ingredient is tirzepatide, made by Eli Lilly. The KwikPen format is identical across the range, a pre-filled, multi-dose device that delivers one weekly subcutaneous injection. The 5 mg version simply contains a higher concentration per dose. There is no reformulation, no different injection technique, and no separate licence. All strengths sit under the same UK marketing authorisation for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. The full Mounjaro overview covers the licence and mechanism in detail if you want the broader picture.

The NHS's tirzepatide information page describes the titration schedule clearly, and it is the first place to read for patient-level guidance on how the doses relate to one another. What matters for anyone searching specifically for the 5 mg pen: it is not a standalone product, and you cannot start treatment at this strength. It follows a period at 2.5 mg, which exists solely to help your body adjust and reduce the likelihood of nausea in those first weeks.

What does the 5 mg dose actually do in the body?

Tirzepatide activates two receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are gut hormones involved in appetite regulation, blood-sugar control and slowing how quickly food moves through the stomach. At 5 mg, this dual action is in full effect. Many people report that the step from 2.5 mg to 5 mg brings a noticeable shift in appetite, meals feel satisfying sooner, the urge to snack reduces, and the background hunger that often undermines other weight-loss attempts quietens. This is not a placebo effect; it reflects the pharmacology. Tirzepatide's dual-agonist mechanism is what distinguishes it from older single-pathway GLP-1 medicines, as explored in the tirzepatide background page.

Side effects can also become more noticeable at 5 mg, simply because the therapeutic effect is higher. Nausea, loose stools, constipation and indigestion are the most commonly reported. For most people these are mild and settle within a few weeks. If they persist or feel severe, the right move is to contact your prescriber, not to reduce the dose without guidance. Eating smaller meals, staying well hydrated and avoiding very fatty or spicy food during the first weeks at any new dose can help considerably.

How long do you stay on the 5 mg pen?

The licensed schedule sets a minimum of four weeks at each dose before any increase. In practice, your prescriber may recommend staying at 5 mg longer if your tolerability was borderline at 2.5 mg, if you are managing other health conditions alongside treatment, or if weight loss is progressing well and there is no clinical reason to go higher. There is no rule that you must reach 15 mg, the right maintenance dose is the highest one you tolerate well that supports your health goals. That is a clinical conversation, not a decision made by reading a dose chart.

For those who want to see how the 5 mg experience compares to higher strengths, the 15 mg Mounjaro page covers the upper end of the schedule and the trial data associated with it. And if you are curious about what people at this dose actually report, our 5ml tirzepatide page and the 5 mg Mounjaro reviews page draw on patient-reported experience in an honest, evidence-grounded way.

Can you buy a 5 mg Mounjaro pen without completing the 2.5 mg step?

No reputable UK prescriber will start tirzepatide treatment at 5 mg. The 2.5 mg pen is a mandatory first step, its purpose is tolerability, not therapeutic effect, and skipping it significantly raises the chance of GI side effects that cause people to abandon treatment unnecessarily. Any seller offering 5 mg pens to someone who has not established clinical suitability and completed the starter phase is not operating within the UK's licensed prescribing framework. The MHRA has warned publicly and repeatedly about websites selling Mounjaro and similar medicines without proper clinical assessment, and about counterfeit pens that have caused serious harm. A GPhC-registered pharmacy (verifiable on the register) is the only safe route.

At nume, every request to move from 2.5 mg to 5 mg is reviewed by a real GPhC-registered Independent Prescriber before dispatch. The review considers your weight, tolerance, medical history and any other relevant information, it takes a few minutes on your part, and the prescriber handles the clinical judgement. For a broader look at what accessing tirzepatide safely involves, the how to get Mounjaro page covers the full process, including what to look for when choosing a provider. If you are weighing the cost context as part of your decision, the weight-loss treatment overview sets out what legitimate private treatment typically involves financially.

Ready to see whether you are a candidate for treatment? Start your free consultation and a prescriber at nume will review your answers the same day.